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Abstract Recent insight into the underlying molecular
and cellular mechanisms of fragile X syndrome (FXS) has
led to the proposal and development of new pharmaceutical
treatment strategies, and the initiation of clinical trials
aimed at correcting core symptoms of the developmental
disorder. Consequently, there is an urgent and critical need
for outcome measures that are valid for quantifying speciﬁc
symptoms of FXS and that are consistent across time. We
used eye tracking to evaluate test–retest reliability of gaze
and pupillometry measures in individuals with FXS and we
demonstrate that these measures are viable options for
assessing treatment-speciﬁc outcomes related to a core
behavioral feature of the disorder.
Keywords Face processing  Gaze  Fixation 
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Introduction
Fragile X syndrome (FXS) is the most common genetic
cause of intellectual impairment (Crawford et al. 2001) and
the most common monogenetic cause of autism (Cohen
et al. 2005). FXS results from an expansion mutation of
greater than 200 CGG trinucleotide repeats in the promoter
region of the fragile X mental retardation 1 (FMR1) gene
on the X chromosome (Verkerk et al. 1991), which is
associated with methylation and transcriptional silencing of
the gene and consequently leads to reduction or complete
absence of fragile X mental retardation protein (FMRP;
(Devys et al. 1993). The lack of FMRP gives rise to
abnormal dendritic spine maturation and synaptic pruning
during brain development (Bagni and Greenough 2005;
Greenough et al. 2001). In addition to mild to severe intel-
lectual impairment, individuals affected by FXS commonly
exhibit behaviors consistent with attention-deﬁcit hyperac-
tivity disorder (ADHD), autism spectrum disorders (ASD),
and social anxiety (for reviews see Hagerman 2002;
Schneider et al. 2009).
Recent advances in translational research have furthered
our understanding of the neurobiology underlying FXS and
have led to a surge in the development of pharmacological
treatments targeted at ameliorating downstream effects of
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development of drug therapies is the ‘‘mGluR theory’’ of
FXS, which suggests that FMRP modulates dendritic
maturation through a mechanism involving the repression
of metabotropic glutamate receptor (mGluR)-mediated
protein synthesis (Bear etal. 2004). Support for this theory
comes from animal studies which have demonstrated that
without the negative feedback provided by FMRP,
mGluR5-dependent hippocampal and cerebellar long-term
depression (LTD) is enhanced, cortical synaptic AMPA
receptor numbers are reduced, and dendritic processes are
structurally immature in the FMR1 knockout mouse (Bear
et al. 2004; Huber et al. 2002; Irwin et al. 2002). These and
other phenotypic abnormalities are rescued in the mouse
(Yan et al. 2005) and fruit ﬂy (McBride et al. 2005) models
of FXS with mGluR5 antagonists such as MPEP (2-methyl-
6-(phenylethynyl)pyridine). The consistency of these
promising results across several laboratories has spurred
the development of mGluR5-antagonists as potential
pharmacotherapies for targeting the underlying neurobio-
logical pathology of FXS (for reviews see Waung and
Huber 2009; Bear 2005).
Phase II neurotherapeutic clinical trials in humans with
FXS are currently in progress and additional trials are
being designed, generating an urgent need for objective,
empirically validated, quantitative outcome measures in
order to assess the efﬁcacy of drug treatments. Outcome
measures based on standardized assessments and parent
questionnaires may be age- or IQ-speciﬁc and are often
susceptible to strong placebo effects and rater bias. Fur-
thermore, these outcome measures often do not address
effects of treatment within a speciﬁc cognitive domain
let alone a speciﬁc neural pathway or system. Psycho-
physiological tasks, on the other hand, offer signiﬁcant
appeal as outcome measures as much of the underlying
neurobiological circuitry involved in these tasks has
already been well characterized in the literature. These
measures are also much less prone to placebo effects and
bias, and may therefore provide greater sensitivity to
treatment efﬁcacy than standardized measures, particularly
in smaller scale Phase II studies. Furthermore, despite
numerous reports of the effectiveness of behavioral inter-
ventions among patients with FXS, biological measures
that can be used to evaluate the speciﬁcity of these pro-
grams are lacking. An example of the utility of psycho-
physiological measures in early-phase clinical trials in FXS
was the demonstration of improvement in prepulse inhi-
bition in an open label, single dose trial of the mGluR5-
blocker fenobam (Berry-Kravis et al. 2009).
Gaze avoidance is a hallmark behavioral feature of FXS
(Cohen et al. 1988; Bregman et al. 1988; Garrett et al.
2004; Farzin et al. 2009; Cohen et al. 1989), and has been
physiologically linked with cortisol dysregulation (Hessl
et al. 2002, 2006) and enhanced autonomic reactivity
(Farzin et al. 2009; Hall et al. 2006, 2009; Belser and
Sudhalter 1995). Findings from neuroimaging studies
suggest atypical neural circuitry involved in face process-
ing and social cognition may exist in individuals in FXS
(Dalton et al. 2007; Holsen et al. 2008). Recent work has
used eye tracking methods to quantify differences in gaze
patterns and pupillary reactivity when adolescents and
adults with and without FXS passively viewed images of
faces, evoking the idea that eye tracking may hold signif-
icant potential as a measure for assessing a speciﬁc core
behavioral and physiological phenotype observed in indi-
viduals with FXS.
The aim of the present study was to examine the fea-
sibility and reliability of eye tracking and pupillometry as
potential outcome measures for evaluating the efﬁcacy of
psychopharmacological treatments in individuals with
FXS. To do so, we utilized a previously developed eye
tracking protocol (Farzin et al. 2009) to quantify gaze
aversion and face-speciﬁc pupillary response across two
test sessions in groups of participants with and without
FXS. Given that the mechanisms and function of mGluR5
likely contribute to core phenotypic features found in
individuals with FXS, we expect that using eye tracking to
measure visual processing of faces will prove particularly
sensitive to assessing treatment-speciﬁc outcomes related
to symptoms of social anxiety and sensory hyperarousal.
Methods
Participants
Participants included 15 individuals with FXS conﬁrmed
by DNA testing to carry the full FMR1 mutation (12 males;
ages 7–51 years) and 20 neurotypically developing (NT)
controls (10 males; ages 7–71 years).Participants were
matched based on chronological age (t (33) = 1.522,
p = 0.138). Individuals with FXS were recruited through
the Fragile X Research Clinic and Research Program at
Rush University Medical Center. NT participants were
recruited from the Rush campus community and local
schools in the Chicago area and were included only if there
was no history of psychiatric diagnosis. All participants
had normal or corrected-to-normal vision. Adult partici-
pants or parents/guardians of child or adult FXS partici-
pants provided written consent according to a protocol
approved by the Institutional Review Board at Rush
University Medical Center.
At the time of testing, 12 individuals with FXS (80% of
the group) were being treated with at least one class of
psychoactive medication; SSRI/SNRI (46%), stimulant
(38%), antipsychotic (31%).
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viduals with FXS (10 males) using the Wechsler Scales of
Intelligence (Wechsler Intelligence Scale for Children,
Fourth Edition; Wechsler Abbreviated Scale of Intelli-
gence; The Psychological Corporation, San Antonio, TX)
or the Stanford Binet, Fifth Edition (Riverside Publishing,
Rolling Meadows, IL). Males with FXS had a mean IQ of
51.8 (SD = 10.9; range = 36–72) and females with FXS
had a mean IQ of 76.3 (SD = 9.3; range = 72–86).
The Aberrant Behavior Checklist (ABC; Aman et al.
1985) is a 58-item rating scale developed for persons with
developmental disabilities and was used to assess mal-
adaptive behaviors including hyperactivity, lethargy/social
withdrawal, inappropriate speech, and irritability in indi-
viduals with FXS.
The Social Responsiveness Scale (SRS;Constantino and
Gruber 2005) was administered to individuals with FXS to
evaluate the severity of autism spectrum symptoms.
Group characteristics are given in Table 1.
Apparatus and Stimuli
A Tobii T120 infrared binocular eye tracker (Tobii Tech-
nology, Sweden) was used to record X and Y coordinates
of eye position and pupil diameter. This video-based sys-
tem consists of a high-resolution camera embedded in a
17-inch thin-ﬁlm transistor LCD monitor (1,280 9 1,024
pixels resolution), which promotes more natural user
behavior since it does not place restraints on participants
such as a helmet, head-mounted sensor, or glasses. The eye
tracker samples the position of the eyes at a rate of 120 Hz
(one data point approximately every 10 ms, with an aver-
age precision of within 0.5 of visual angle).
Stimuli were identical to those used by Farzin et al.
(2009). Images consisted of 60 colored photographs of
adult human faces (equal numbers of males and females;
different races and ethnicities) from the NimStim Face
Stimulus Set (Tottenham et al. 2002), each face exhibiting
a calm, happy, or fearful expression, and 60 scrambled
versions of the face images. To insure that pupillary
response to the onset of a face was independent of
a pupillary light reﬂex, each face and corresponding
scrambled image were matched on mean luminance, and
equivalence was conﬁrmed using a photometer (Minolta,
LS-100, Osaka, Japan). Face images subtended a 12.12 by
17.19 region (the size of an actual human face) when
viewed from a distance of 60 cm, and were presented on a
standard 50% grey background (RGB: 128, 128, 128).
Procedure
Testing was conducted in a quiet room with the lights
turned off. The eye tracker was calibrated for each
participant at the beginning of each session using a stan-
dardized 9-point routine. Following calibration, partici-
pants were told to view the pictures shown on the screen.
Each trial began with presentation of a scrambled face
image for 1 s followed immediately by its matched face
image for 3 s. An inter-trial interval (ITI) containing a
uniform grey screen was shown for 0.5, 1, or 2 s, randomly
determined. The order of face presentation was pseudor-
andomized and each eye tracking session lasted approxi-
mately 6 min. All measurements were analyzed ofﬂine.
Test–retest reliability of eye tracking measures was
assessed based on two testing sessions separated by no
more than 2 weeks. This time interval was chosen in order
to match the time frame between clinic visits used in the
protocol of an ongoing clinical trial. Test–retest intervals
were equivalent between groups (NT controls: 9 days,
FXS: 10 days; [t (33) =- 0.930, p = 0.359]).
Analyses
Four area-of-interest (AOI) regions were deﬁned for each
face image: eyes (including the eyebrows), nose, mouth,
and other. Scrambled faces included a single AOI around
the ellipse. Measures included number of ﬁxations (where a
ﬁxation was deﬁned as any data point within a 30 pixel
radius for a minimum duration of 150 ms) and proportion
of looking time to each AOI region (calculated by dividing
looking time to AOI region by total looking time to face).
Pupil data were ﬁltered to remove points in which both
eyes were not successfully recorded, outlier values corre-
sponding to blinks, loss of tracking data, or large changes
in head position, and trials in which the participant did not
look at the preceding scrambled face image for 3 or more
consecutive 250 ms intervals (rendering the baseline pupil
diameter invalid). Mean pupil diameter was calculated for
interval durations of 250 ms across the 3-s face presenta-
tion (12 intervals), time-locked to the onset of the image.
Table 1 Participant characteristics by group (mean ± SD)
FXS (N = 15) NT controls
(N = 20)
Gender (M:F) 12:3 10:10
Chronological age (years) 18.8 ± 10.7 24.9 ± 12.5
Full scale IQ
a 57.5 ± 14.5
ABC total 23.2 ± 19.3
SRS total 77.9 ± 32.7
Test–retest interval (days) 10.6 ± 6.3 9.1 ± 3.5
FXS fragile X syndrome, NT Neurotypical, M male, F female, ABC
Abberant Behavior Checklist, SRS Social Responsiveness Scale
a Intellectual level was measured using the Weschler Intelligence
Scales, N = 13
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speciﬁc pupillary response: mean pupil diameter during
face presentation interval—mean pupil diameter during the
scrambled face presentation. To provide a relative change,
we ‘‘standardized’’ this difference value by dividing it by
the mean pupil diameter during the scrambled face pre-
sentation. Relative change in pupil diameter was averaged
across trials of each face emotion. Pupillary response
during each interval of the scrambled face presentation (4
intervals) was calculated with respect to the mean pupil
diameter during the ITI interval period.
Results
All participants successfully completed the experimental
procedure during both testing sessions. Individuals with
and without FXS provided gaze data for a comparable
number of slides of each emotion type across sessions
[F (2, 32) = 0.912, p = 0.412], allowing us to rule out
possible confounds such as differences in attention to faces
or general motivation between groups.
Replicating ﬁndings reported in Farzin et al. (2009),
individuals with FXS made fewer ﬁxations to and spent
less time looking at the eye region of all faces, relative to
the NT control group, during both testing sessions (Fig. 1).
A repeated measures analysis of variance (ANOVA) with
AOI region (eye, nose, mouth, and other), emotion (calm,
happy and fear), testing session (1 and 2), and group (FXS
and NT) as independent variables and number of ﬁxations
as the dependent variable revealed signiﬁcant main effects
of AOI region [F (3, 31) = 22.73, p = 0.0001, g
2 = 0.687]
and emotion [F (2, 32) = 4.029, p = 0.028, g
2 = 0.201],
and signiﬁcant interaction effects between AOI region and
group [F (3, 31) = 6.12, p = 0.002, g
2 = 0.372] and
emotion and group [F (2, 32) = 4.711, p = 0.016,
g
2 = 0.227]. No effect of session was found [F (1,
33) = 0.280, p = 0.460]. Independent-samples t-tests
conﬁrmed that, compared to controls, individuals with FXS
made fewer ﬁxations to the eye region of all face images
(FXS M = 1.61, SD = 1.04; NT M = 3.99, SD = 1.59;
[t (33) = 5.01, p = 0.0001]) and made fewer overall ﬁx-
ations when the happy (FXS M = 2.48, SD = 1.22; NT
M = 3.53, SD = 1.19; [t (33) = 3.28, p = 0.002]) and
calm (FXS M = 2.47, SD = 1.21; NT M = 3.48,
SD = 1.18; [t (33) = 2.05, p = 0.049]) faces were on the
screen.
A similar repeated measures ANOVA was conducted
using proportion of looking time as the dependent variable,
which also yielded a main effect of AOI region [F (3,
31) = 22.87, p = 0.0001, g
2 = 0.689] and a signiﬁcant
interaction effect between AOI region and group [F (3,
31) = 8.711, p = 0.0001, g
2 = 0.457]. A signiﬁcant
interaction effect between AOI region and emotion was
identiﬁed [F (6, 28) = 6.71, p = 0.0001, g
2 = 0.590],
driven by generally longer looking to the mouth region of
happy faces compared to either of the other two emotions.
No effect of session was observed [F (1, 33) = 0.626,
p = 0.435]. Independent-samples t tests qualiﬁed that,
across both sessions, individuals with FXS spent approxi-
mately half as much time looking at the eye region (FXS:
M = 16.2%, SD = 11.41; NT: M = 28.3%, SD = 10.04;
[t (33) = 3.33, p = 0.002]) and a larger proportion of time
looking at the mouth region (FXS M = 42.1, SD = 12.19;
Fig. 1 Mean number of ﬁxations to each AOI region by group for test sessions 1 and 2. Error bars represent the standard errors of the mean.
Asterisk and double asterisk indicate signiﬁcant difference between pairwise comparisons at the p\0.05 and p\0.01 level, respectively
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of all faces, compared to controls (Fig. 2).
Importantly, no group difference was found for the
number of ﬁxations made to [F (1, 33) = 0.710,
p = 0.405, g
2 = 0.21], or time spent looking at [F (1,
33) = 2.782, p = 0.105, g
2 = 0.780], the scrambled ima-
ges across sessions, suggesting that the group differences in
gaze behavior were face-speciﬁc. Within the group of
individuals with FXS, no effect of gender was found for
number of ﬁxations made to the eye region of faces [F (1,
14) = 0.008, p = 0.929], or proportion of time spent
looking at the eye region of faces [F (1, 14) = 0.266,
p = 0.614] across the two sessions, suggesting that there
was no difference in the extent of eye gaze avoidance
between males and females with FXS. Likewise, age was
not associated with number of ﬁxations made to the eye
region of faces [F (1, 14) = 0.487, p = 0.83], or propor-
tion of time spent looking at the eye region of faces [F (1,
14) = 1.526, p = 0.463] across the two sessions in indi-
viduals with FXS. Sex and age yielded no effects within the
control group either.
Individuals with FXS demonstrated signiﬁcantly greater
pupillary dilation in response to faces, relative to controls,
replicating results of Farzin et al. (2009). A repeated
measures ANOVA with interval (12), emotion, and test
session as independent variables and face-speciﬁc change
in pupil diameter as the dependent variable was conducted
within each group. A signiﬁcant main effect of interval
revealed that pupil diameter increased across time in both
groups (FXS: [F (11, 4) = 9.67, p = 0.021, g
2 = 0.964],
NT: [F (11, 9) = 19.96, p = 0.0001, g
2 = 0.961]). This
dilation was not modulated by face emotion or session for
either group, as illustrated in the scatterplots presented in
Fig. 3. We also analyzed pupillary response with group as
a between-subject factor and conﬁrmed that, in addition to
a signiﬁcant main effect of interval [F (11, 23) = 14.14,
p = 0.0001, g
2 = 0.871], individuals with FXS generally
experienced greater pupil dilation than NTs (FXS:
M = 0.018 SD = 0.03, NT: M = 0.003 SD = 0.02; [F (1,
33) = 4.68, p = 0.038, g
2 = 0.124]). Pupillary reactivity
to the onset of scrambled faces did not differ between
groups [F (1, 34) = 1.980, p = 0.169] or as a function of
session [F (1, 33) = 2.044, p = 0.162].
Since we were primarily interested in the test–retest
stability of ﬁxation count, looking time, and pupillary
response measures as potential metrics of change for
treatment outcome studies, we computed the intraclass
correlation coefﬁcient (Bradley et al. 2008) between ses-
sions for each group using a two-factor mixed-effects
consistency model. If participants performed identically on
the two occasions, the ICC value will indicate perfect
association and agreement, and will be equal to 1. Because
a group difference in gaze behavior was found across all
faces, we removed emotion as a factor for the reliability
analyses. Pupillary response was averaged across intervals
for the reliability analyses. A high degree of reliability was
found for all measures; ICCs demonstrated good
(ICC[0.40) to excellent (ICC[0.75) test–retest repro-
ducibility in both groups (Table 2). In the FXS group,
number of ﬁxations and proportion looking time to the eye
and nose regions were exceptionally high (ICC[0.90)
relative to controls. Pupillometry in response to fear faces
was most reproducible in individuals with FXS
(ICC = 0.87).
Fig. 2 Mean proportion looking time to each AOI region by group for test sessions 1 and 2. Error bars represent the standard errors of the mean.
Asterisk and double asterisk indicate signiﬁcant difference between pairwise comparisons at the p\0.05 and p\0.01 level, respectively
J Autism Dev Disord (2011) 41:1515–1522 1519
123Discussion
The main goal of this study was to investigate the test–
retest reliability of eye tracking measures in individuals
with FXS in order to establish their potential utility for use
in clinical drug trials. Here, we present gaze position and
pupillometry data recorded while individuals with and
without FXS viewed images of faces, collected during two
separate test sessions. These data reveal substantial quan-
titative differences in face processing and autonomic
reactivity between groups, replicating Farzin et al. (2009).
Most importantly, repeated assessment using these eye
tracking measures within the same sample of participants
yielded high reliability for both groups. The reduced
between-subject variance present in the NT group relative
to that of the FXS group may explain the lower ICC values
obtained for a few of the eye tracking measures in the NT
group. To our knowledge, this is the ﬁrst study to dem-
onstrate test–retest reliability of eye tracking in this
developmentally delayed population. All individuals with
FXS were able to complete both test sessions, regardless of
age, social function, or IQ, suggesting that this protocol
could be effectively used in a clinical trial enrolling chil-
dren, adolescents, and adult individuals with FXS of a
broad range of functioning. Further, individuals with FXS
with a wide range of behavioral severity on the ABC were
Fig. 3 Mean relative change in pupil diameter (mm) in response to
calm, happy, and fear faces for individual participants in each group.
On the X-axis are data from test session 1 and on the Y-axis are data
from test session 2
Table 2 Test-retest reliability (Intraclass Correlation Coefﬁcient) of
eye tracking measures between test sessions 1 and 2, by group
FXS NT controls
Number of ﬁxations
Eyes 0.90 0.56
Nose 0.95 0.85
Mouth 0.81 0.83
Scrambled 0.80 0.77
Proportion looking time
Eyes 0.93 0.68
Nose 0.94 0.86
Mouth 0.97 0.63
Scrambled 0.64 0.40
Pupillary response
Calm 0.51 0.91
Happy 0.66 0.92
Fear 0.87 0.95
Scrambled 0.32 0.90
b
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FXS having sufﬁcient behavioral dysfunction on the ABC
to qualify for clinical trials will still be able to do the task.
The selection of appropriate outcome measures that are
both psychometrically valid and reliable internally, across
raters, and across time, is critical for clinical drug trials.
Our data suggest that eye tracking and pupillometry are
reliable measures for evaluating changes associated with
treatments.
Researchers have suggested that social avoidance/anxi-
etyingeneral,andgaze aversionspeciﬁcally,maybecoping
strategies that serve to reduce negative arousal in individ-
uals with FXS (Garrett et al. 2004; Farzin et al. 2009; Hessl
et al. 2006). A recent study has shown that eye contact in
children with FXS is amenable to improvement through
behavioral training (Hall et al. 2009). While the exact bio-
logical bases for differences in gaze behaviors are not fully
understood, research has shown that secretion of cortisol, by
means of a cascade of hormones along the hypothalamic–
pituitary–adrenal (HPA) axis, involves feedback between
several limbic structures, among which the amygdala plays
a leading role. Long-term potentiation in the amygdala
requires activation of mGluR5 and is impaired in FXS
knockout mice (Zhao et al. 2005; Suvrathan et al. 2010;
Rodrigues et al. 2002). The present protocol, if used to test
the efﬁcacy of neurotherapeutic agents such as mGluR5
antagonists, would provide information regarding not only
the therapeutic potential for social anxiety in FXS, but also
the primary site(s) and mechanism(s) of action of the drug.
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